PMN Valuation
ProMIS Neurosciences Inc
$
0.514
- Overview
- Forecast
- Valuation
PMN Relative Valuation
PMN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PMN is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for PMN's competitors is 9.04, providing a benchmark for relative valuation. ProMIS Neurosciences Inc Corp (PMN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
ORCL
Oracle Corp
160.490
USD
+0.68%
TSLA
Tesla Inc
349.980
USD
+2.09%
MSFT
Microsoft Corp
454.270
USD
+0.25%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
AAPL
Apple Inc
211.260
USD
-0.09%
AVGO
Broadcom Inc
228.610
USD
-1.73%
META
Meta Platforms Inc
640.340
USD
-0.55%
WMT
Walmart Inc
98.240
USD
+1.96%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
FAQ
Is ProMIS Neurosciences Inc (PMN) currently overvalued or undervalued?
ProMIS Neurosciences Inc (PMN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 2114.70. The fair price of ProMIS Neurosciences Inc (PMN) is between to according to relative valuation methord.
What is ProMIS Neurosciences Inc (PMN) fair value?
How does PMN's valuation metrics compare to the industry average?
What is the current P/B ratio for ProMIS Neurosciences Inc (PMN) as of May 18 2025?
What is the current FCF Yield for ProMIS Neurosciences Inc (PMN) as of May 18 2025?
What is the current Forward P/E ratio for ProMIS Neurosciences Inc (PMN) as of May 18 2025?